The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer
The clinical significance of transforming acidic coiled-coil protein 3 expression in non-small cell lung cancer
复制标题
转化酸性卷曲螺旋蛋白3在非小细胞肺癌中表达的临床意义
DOI：
10.3892/or.2015.4373
复制
发表时间：
2016-01-01
期刊：
影响因子：
4.2
通讯作者：
Zhang, Xing
中科院分区：
文献类型：
--
作者：
Jiang, Feng;Kuang, Bohua;Zhang, Xing
转化酸性卷曲螺旋蛋白（TACCs）家族成员TACC 3与肺癌之间的关系尚不清楚。本研究旨在探讨TACC 3在非小细胞肺癌（NSCLC）中的预后和临床意义。采用免疫组织化学方法检测195例肺癌组织中TACC 3的表达。通过定量逆转录-PCR或蛋白质印迹法检测TACC 3的mRNA和蛋白水平。采用卡方检验和Fisher精确检验分析TACC 3表达与临床病理因素的相关性。Kaplan-Meier分析和考克斯比例风险模型用于检查预后结果与TACC 3的相关性。结果显示，肺癌组织中TACC 3 mRNA和总蛋白的表达水平均高于癌旁组织。免疫组化结果显示，94例（48.2%）TACC 3高表达。TACC 3的表达与吸烟状况、组织学类型、分化程度、细胞角蛋白19片段水平、T分期及临床分期密切相关。单因素和多因素分析表明，TACC 3是NSCLC预后的有用生物标志物。在接受抗微管化疗的患者中，低TACC 3表达组表现出更好的无进展生存期（PFS）。总之，结果表明，高水平的TACC 3表达与NSCLC患者的晚期临床病理分类、较差的总生存期（OS）和较差的无复发生存期（RFS）相关。我们的研究结果表明，TACC 3是一个潜在的预后标志物和NSCLC的治疗靶点。
The relationship between TACC3, a member of the transforming acidic coiled-coil proteins (TACCs) family, and lung carcinoma remains unclear. The present study was designed to explore the prognostic and clinical significance of TACC3 in non-small cell lung cancer (NSCLC). An immunohistochemistry (IHC) assay was performed to analyze the expression of TACC3 in 195 lung cancer cases. The mRNA and protein levels of TACC3 were examined by quantitative reverse transcription-PCR or western blotting. The correlation between TACC3 expression and clinicopathological factors was analyzed by chi(2) analysis and Fisher's exact test. Kaplan-Meier analysis and the Cox proportional hazards model were used to examine the correlation of prognostic outcomes with TACC3. The results showed that the levels of TACC3 mRNA and total protein were higher in lung cancer lesions than paired non-cancerous tissues. IHC analysis revealed that TACC3 was highly expressed in 94(48.2%) cases. The expression of TACC3 was strongly correlated with smoking status, histological classification, differentiation, cytokeratin 19 fragment levels, T stage and the clinical stage of NSCLC patients. Univariate and multivariate analyses demonstrated that TACC3 is a useful biomarker for NSCLC prognosis. The low TACC3 expression group exhibited better progression-free survival (PFS) among patients who received anti-microtubule chemotherapy. In conclusion, the results showed that a high level of TACC3 expression was correlated with advanced clinicopathological classifications, poor overall survival (OS) and poor recurrence-free survival (RFS) in NSCLC patients. Our findings indicate that TACC3 is a potential prognostic marker and therapeutic target for NSCLC.